Net Loss of Wockhardt reported to Rs 22.00 crore in the quarter ended September 2024 as against net loss of Rs 77.00 crore during the previous quarter ended September 2023. Sales rose 7.44% to Rs 809.00 crore in the quarter ended September 2024 as against Rs 753.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales809.00753.00 7 OPM %13.609.56 - PBDT46.0020.00 130 PBT-9.00-35.00 74 NP-22.00-77.00 71 Powered by Capital Market - Live

Wockhardt will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

The floor price indicates a steep discount of 8.5% over the stock's closing price on Wednesday. The media reported that the QIP is aimed to raise up to Rs 1,000 crore, with an additional greenshoe option of Rs 200 crore. A QIP is a method by which a company raises funds by allotting shares to eligible institutional buyers. According to reports, the QIP is expected to dilute Wockhardt's equity by around 5.57% of its post-issue capital. Based on the September shareholding pattern, promoters of Wockhardt held a 51.99% stake in the company. Mumbai-based Wockhardt is a research based global pharmaceutical and biotech company. Employing around ~2600 people and 27 nationalities, it has a presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland. Around 78% of its global revenues is coming from international businesses. Powered by Capital Market - Live

Wockhardt announced the filing of its fast-acting insulin analog, Aspart injection (ASPARAPID), with the Drugs Controller General of India (DCGI). This significant milestone reflects Wockhardt's ongoing commitment to address the growing diabetes epidemic both in India and globally. Wockhardt's Aspart insulin injection (ASPARAPID) is an indigenously developed product, underscoring the company's end-to-end capabilities in research development - from research to production through in-house development. It offers enhanced quality and accessibility for patients. ASPARAPID will be available in cartridges, vials, and prefilled disposable pens, offering flexibility to the patients for management of diabetes. The market size of Aspart in India is currently estimated over Rs 260 crore with only 2 players and is expected to grow significantly in the coming years. 'We are proud of adding another feather in our diabetes biosimilars portfolio through filing of insulin Aspart injection in a market that has limited competition. This reinforces Wockhardt's ability to develop and manufacture complex biosimilars domestically,' said Dr. Habil Khorakiwala, Founder Chairman of Wockhardt. 'Our aim is to make world-class diabetes care accessible to patients in India and globally and to contribute meaningfully to the management of diabetes.' Wockhardt is also developing additional insulin analogs and GLP-1 agonists as part of its comprehensive strategy to provide advanced diabetes care solutions. The introduction of these products will further strengthen Wockhardt's diabetes portfolio, offering patients more effective treatment options for managing their condition. Powered by Capital Market - Live

Wockhardt is advancing the development of several new antibiotics aimed at combating difficult-to-treat drug-resistant bacterial infections that drive anti-microbial resistance (AMR) linked mortality and morbidity. Recently, one of its unique once-a-day, '-lactam enhancer based MDR-active antibiotic, WCK 6777 (Ertapenem/Zidebactam) has successfully completed a Phase I study conducted by the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in US. Recognizing the therapeutic potential of WCK 6777 for infections caused by MDR Gram negative pathogens, DMID of NIH had selected this drug for Phase I studies. Zidebactam has already demonstrated promising safety profile in Phase I and on-going Phase II & III studies in combination with Cefepime (WCK 5222). Additionally, recognizing its potential to meet significant unmet medical needs, the US FDA has recently granted Fast Track designation to WCK 6777 for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI). WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy (OPAT) in ambulatory settings. WCK 6777 is active against entire range of meropenem-resistant Gram negative pathogens generally encountered in community as well as hospital urinary tract infections (UTI) and intra-abdominal infections (IAI). Such a therapeutic option is expected to cut hospital admissions, facilitate early patient discharge and thus offer patient-centred care for MDR infections. Phase I study of WCK 6777 involved 52 participants and was designed as a double-blind, placebo-controlled, multiple-ascending dose trial in healthy volunteers. The trial rigorously assessed the safety and pharmacokinetics of WCK 6777, administering intravenous doses higher than the anticipated clinical dose over a period of 7 days. Results demonstrated a promising safety profile, with WCK 6777 (up to 3 grams + 3 grams daily) being well-tolerated, and no serious or unexpected adverse events reported. None of the subjects withdrew or were discontinued from the study due to treatment-related adverse events. Pharmacokinetic analysis revealed consistent exposure levels of both ertapenem and zidebactam, with no significant interactions when co-administered daily for the duration of the study. The promising safety data from this study paves the way for the advancement of WCK 6777 into Phase II / III clinical trials. Globally, incidence of UTI were 404.61 million with 236,790 deaths estimated in 2019. It is estimated that 1 in 100 of US adults will experience a cUTI each year, resulting in approximately 2.8 million cUTI cases and annualized total US costs in excess of $ 6 billion. There are 600,000 hospital admissions among adults for cUTIs each year in the United States with each episode costing an average of $ 9,441. Emerging therapeutic role of WCK 6777 makes it uniquely positioned to cater to the vast unmet need in the management of infections outside the hospital.Powered by Capital Market - Live

Wockhardt announced that Tasneem Vikram Singh Mehta (DIN: 05009664) ceased to be Independent Director of the Company upon completion of her second term of 5 (Five) consecutive years on 29 September 2024.Powered by Capital Market - Live

In the past year, Wockhardt's investigational drug, Zaynich' (Zidebactam/Cefepime), has successfully treated over 35 critically ill patients in India and US who were suffering from extremely drug-resistant infections under compassionate use. This drug has once again demonstrated its effectiveness in managing complex, deep-seated infections. A recent notable case involved a 64-year-old patient with Type 2 diabetes and hypertension, who had been battling pulmonary and meningeal tuberculosis for about a year. Following a spinal puncture to withdraw cerebrospinal fluid (CSF), the patient developed fever, drowsiness, and unconsciousness, leading to mechanical ventilation and a diagnosis of bacterial meningitis. The condition was confirmed when CSF analysis identified a pan-drug resistant super-bug, Pseudomonas. Initial treatments with Ceftazidime/Avibactam, Aztreonam, and Meropenem failed to halt the patient's deterioration, marked by persistent fever spikes and increasing infection markers such as C-Reactive Protein (CRP), procalcitonin, and white blood cells (WBC). Due to the significant toxicity and limited ability of Colistin and Polymyxin in crossing the blood-brain barrier, these options were deemed unsuitable. Faced with no alternatives, a multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use. Treatment was administered for three weeks. Remarkably, within a short period, the patient's clinical condition improved, with CRP and procalcitonin levels decreasing, and the patient was successfully taken off the ventilator. CSF tests showed the eradication of the pathogen just one week into treatment, and subsequent tests confirmed the absence of Pseudomonas after three weeks of Zidebactam/Cefepime. The patient became clinically stable and all symptoms resolved leading to discharge from the hospital. The drug was well-tolerated throughout the treatment period. Meningitis, an inflammation of the tissues surrounding the brain and spinal cord, poses significant treatment challenges due to the difficulty of antibiotics in penetrating the blood-brain barrier. This case highlights Zidebactam/Cefepime's remarkable ability to tackle infections in difficult-to-treat body sites. This represents the first case of nosocomial meningitis caused by multidrug-resistant Pseudomonas successfully treated with Zidebactam/Cefepime, underscoring its potential as a valuable therapeutic option. Zaynich, combination of Cefepime and Zidebactam, is Wockhardt's novel patented antibiotic, targeted towards multi-drug resistant Gram-negative infections. It is currently undergoing a multi-national Phase III study which would support its registration/marketing authorization globally. Earlier, multiple Phase I studies including clinical pharmacology studies with Zidebactam/Cefepime were conducted in US. Zaynich (Zidebactam/Cefepime) is also undergoing a Phase II study in India for the treatment of carbapenem-resistant infections.Powered by Capital Market - Live

Wockhardt has allotted 8,610 equity shares under ESOS in 26 August 2024. With this allotment, the paid-up equity share capital of the Company will increase from Rs.76,70,04,680/- (15,34,00,936 equity shares of Rs.5/- each) to Rs. 76,70,47,730/- (15,34,09,546 equity shares of Rs.5/- each).Powered by Capital Market - Live

Net Loss of Wockhardt reported to Rs 14.00 crore in the quarter ended June 2024 as against net loss of Rs 134.00 crore during the previous quarter ended June 2023. Sales rose 14.75% to Rs 739.00 crore in the quarter ended June 2024 as against Rs 644.00 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales739.00644.00 15 OPM %12.312.48 - PBDT48.00-49.00 LP PBT-6.00-104.00 94 NP-14.00-134.00 90 Powered by Capital Market - Live

Wockhardt will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live